NEW YORK (GenomeWeb) – MolecularMD has partnered with Asterand Bioscience to provide its biopharma customers with an end-to-end workflow for biomarker and cancer drug target validation, and assay development, the companies announced today.
Under the terms of the deal, MolecularMD will access Asterand's human tissue procurement, characterization, and research services to assist with the development of custom clinical trial assays and companion diagnostic products for its clients. Specific details were not disclosed.
The alliance, MolecularMD President and CEO Dan Snyder said in a statement, "will help our broad client base accelerate their pipeline decisions and dramatically improve the efficiency of the clinical trial and commercialization workflow."